hPG<sub>80</sub> (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors
Current blood-based biomarkers for neuroendocrine neoplasms (NENs) lack both sensitivity and specificity. Human circulating progastrin (hPG<sub>80</sub>) is a novel biomarker that can be easily measured in plasma by ELISA. This study is the first to examine hPG<sub>80</sub> i...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/4/863 |
| _version_ | 1797482142859526144 |
|---|---|
| author | Aman Chauhan Alexandre Prieur Jill Kolesar Susanne Arnold Léa Payen Younes Mahi Berengere Vire Madison Sands B. Mark Evers Dominique Joubert Lowell Anthony |
| author_facet | Aman Chauhan Alexandre Prieur Jill Kolesar Susanne Arnold Léa Payen Younes Mahi Berengere Vire Madison Sands B. Mark Evers Dominique Joubert Lowell Anthony |
| author_sort | Aman Chauhan |
| collection | DOAJ |
| description | Current blood-based biomarkers for neuroendocrine neoplasms (NENs) lack both sensitivity and specificity. Human circulating progastrin (hPG<sub>80</sub>) is a novel biomarker that can be easily measured in plasma by ELISA. This study is the first to examine hPG<sub>80</sub> in NENs. Plasma hPG<sub>80</sub> was quantified from 95 stage IV NEN patients, using DxPG<sub>80</sub> technology (ECS Progastrin, Switzerland) and compared with hPG<sub>80</sub> concentrations in two cohorts of healthy donor controls aged 50–80 (<i>n</i> = 252) and 18–25 (<i>n</i> = 137). Median hPG<sub>80</sub> in NENs patients was 5.54 pM compared to 1.5 pM for the 50–80 controls and 0.29 pM the 18–25 cohort (<i>p</i> < 0.0001). Subgroup analysis revealed median hPG<sub>80</sub> levels significantly higher than for either control cohort in neuroendocrine carcinoma (NEC; <i>n</i> = 25) and neuroendocrine tumors (NET; <i>n</i> = 70) including the small-cell lung cancer (SCLC) sub-cohort (<i>n</i> = 13). Diagnostic accuracy, estimated by AUCs, was high for NENs, as well as both sub-groups (NEC/NET) when compared to the younger and older control groups. Plasma hPG<sub>80</sub> in NENs may be a diagnostic blood biomarker for both low- and high-grade NENs; further study is warranted. A prospective multi-center trial is ongoing in NET to evaluate hPG<sub>80</sub> as a means of monitoring disease (NCT04750954). |
| first_indexed | 2024-03-09T22:25:05Z |
| format | Article |
| id | doaj.art-6dd6721d72fb4668b39b3e4c67adbcf9 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T22:25:05Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-6dd6721d72fb4668b39b3e4c67adbcf92023-11-23T19:07:36ZengMDPI AGCancers2072-66942022-02-0114486310.3390/cancers14040863hPG<sub>80</sub> (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine TumorsAman Chauhan0Alexandre Prieur1Jill Kolesar2Susanne Arnold3Léa Payen4Younes Mahi5Berengere Vire6Madison Sands7B. Mark Evers8Dominique Joubert9Lowell Anthony10Division of Medical Oncology, and the Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USAECS Progastrin, 1004 Lausanne, SwitzerlandCollege of Pharmacy, and the Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USADivision of Medical Oncology, and the Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USALyon Sud Hospital, 69310 Pierre-Benite, FranceECS Progastrin, 1004 Lausanne, SwitzerlandECS Progastrin, 1004 Lausanne, SwitzerlandSchool of Medicine, University of Kentucky, Lexington, KY 40536, USADepartment of Surgery, and the Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USAECS Progastrin, 1004 Lausanne, SwitzerlandDivision of Medical Oncology, and the Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USACurrent blood-based biomarkers for neuroendocrine neoplasms (NENs) lack both sensitivity and specificity. Human circulating progastrin (hPG<sub>80</sub>) is a novel biomarker that can be easily measured in plasma by ELISA. This study is the first to examine hPG<sub>80</sub> in NENs. Plasma hPG<sub>80</sub> was quantified from 95 stage IV NEN patients, using DxPG<sub>80</sub> technology (ECS Progastrin, Switzerland) and compared with hPG<sub>80</sub> concentrations in two cohorts of healthy donor controls aged 50–80 (<i>n</i> = 252) and 18–25 (<i>n</i> = 137). Median hPG<sub>80</sub> in NENs patients was 5.54 pM compared to 1.5 pM for the 50–80 controls and 0.29 pM the 18–25 cohort (<i>p</i> < 0.0001). Subgroup analysis revealed median hPG<sub>80</sub> levels significantly higher than for either control cohort in neuroendocrine carcinoma (NEC; <i>n</i> = 25) and neuroendocrine tumors (NET; <i>n</i> = 70) including the small-cell lung cancer (SCLC) sub-cohort (<i>n</i> = 13). Diagnostic accuracy, estimated by AUCs, was high for NENs, as well as both sub-groups (NEC/NET) when compared to the younger and older control groups. Plasma hPG<sub>80</sub> in NENs may be a diagnostic blood biomarker for both low- and high-grade NENs; further study is warranted. A prospective multi-center trial is ongoing in NET to evaluate hPG<sub>80</sub> as a means of monitoring disease (NCT04750954).https://www.mdpi.com/2072-6694/14/4/863circulating progastrinhPG<sub>80</sub>blood-based diagnostic biomarkerneuroendocrine neoplasmsneuroendocrine tumorsneuroendocrine carcinoma |
| spellingShingle | Aman Chauhan Alexandre Prieur Jill Kolesar Susanne Arnold Léa Payen Younes Mahi Berengere Vire Madison Sands B. Mark Evers Dominique Joubert Lowell Anthony hPG<sub>80</sub> (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors Cancers circulating progastrin hPG<sub>80</sub> blood-based diagnostic biomarker neuroendocrine neoplasms neuroendocrine tumors neuroendocrine carcinoma |
| title | hPG<sub>80</sub> (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors |
| title_full | hPG<sub>80</sub> (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors |
| title_fullStr | hPG<sub>80</sub> (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors |
| title_full_unstemmed | hPG<sub>80</sub> (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors |
| title_short | hPG<sub>80</sub> (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors |
| title_sort | hpg sub 80 sub circulating progastrin a novel blood based biomarker for detection of poorly differentiated neuroendocrine carcinoma and well differentiated neuroendocrine tumors |
| topic | circulating progastrin hPG<sub>80</sub> blood-based diagnostic biomarker neuroendocrine neoplasms neuroendocrine tumors neuroendocrine carcinoma |
| url | https://www.mdpi.com/2072-6694/14/4/863 |
| work_keys_str_mv | AT amanchauhan hpgsub80subcirculatingprogastrinanovelbloodbasedbiomarkerfordetectionofpoorlydifferentiatedneuroendocrinecarcinomaandwelldifferentiatedneuroendocrinetumors AT alexandreprieur hpgsub80subcirculatingprogastrinanovelbloodbasedbiomarkerfordetectionofpoorlydifferentiatedneuroendocrinecarcinomaandwelldifferentiatedneuroendocrinetumors AT jillkolesar hpgsub80subcirculatingprogastrinanovelbloodbasedbiomarkerfordetectionofpoorlydifferentiatedneuroendocrinecarcinomaandwelldifferentiatedneuroendocrinetumors AT susannearnold hpgsub80subcirculatingprogastrinanovelbloodbasedbiomarkerfordetectionofpoorlydifferentiatedneuroendocrinecarcinomaandwelldifferentiatedneuroendocrinetumors AT leapayen hpgsub80subcirculatingprogastrinanovelbloodbasedbiomarkerfordetectionofpoorlydifferentiatedneuroendocrinecarcinomaandwelldifferentiatedneuroendocrinetumors AT younesmahi hpgsub80subcirculatingprogastrinanovelbloodbasedbiomarkerfordetectionofpoorlydifferentiatedneuroendocrinecarcinomaandwelldifferentiatedneuroendocrinetumors AT berengerevire hpgsub80subcirculatingprogastrinanovelbloodbasedbiomarkerfordetectionofpoorlydifferentiatedneuroendocrinecarcinomaandwelldifferentiatedneuroendocrinetumors AT madisonsands hpgsub80subcirculatingprogastrinanovelbloodbasedbiomarkerfordetectionofpoorlydifferentiatedneuroendocrinecarcinomaandwelldifferentiatedneuroendocrinetumors AT bmarkevers hpgsub80subcirculatingprogastrinanovelbloodbasedbiomarkerfordetectionofpoorlydifferentiatedneuroendocrinecarcinomaandwelldifferentiatedneuroendocrinetumors AT dominiquejoubert hpgsub80subcirculatingprogastrinanovelbloodbasedbiomarkerfordetectionofpoorlydifferentiatedneuroendocrinecarcinomaandwelldifferentiatedneuroendocrinetumors AT lowellanthony hpgsub80subcirculatingprogastrinanovelbloodbasedbiomarkerfordetectionofpoorlydifferentiatedneuroendocrinecarcinomaandwelldifferentiatedneuroendocrinetumors |